Carbamate esters of eseroline having anticholinesterase activity, a process for their preparation and relative pharmaceutical compositions containing them as the active principle
申请人:MAGIS FARMACEUTICI S.p.A.
公开号:EP0513703A2
公开(公告)日:1992-11-19
Carbamate esters of eseroline having anticholinesterase activity characterized by the following formula (I):
wherein W is a substituent, as defined in the following Specification, HY is a pharmaceutically acceptable organic or inorganic acid x may be 0, 1, 2 and 3 in case of monofunctional acids provided that x is 3 only when W is
or 1/2 and 1/3 in case of bifunctional or trifunctional acids, a process for their preparation and pharmaceutical compositions containing said compounds , as the active principles, for the treatment of diseases associated with cholinergic disorders.
具有抗胆碱酯酶活性的艾舍啉氨基甲酸酯,其特征为下式(I):
其中 W 是取代基,定义见下文说明书,HY 是药学上可接受的有机酸或无机酸 x 在单官能团酸的情况下可以是 0、1、2 和 3,但只有当 W 是时 x 才是 3。
如果是双官能或三官能酸,x 可以是 0、1、2 和 3;如果是双官能或三官能酸,x 可以是 1/2 和 1/3;制备方法和含有上述化合物作为活性成分的药物组合物,用于治疗与胆碱能紊乱有关的疾病。